"The closer to time zero you can treat, the less bleeding you are likely to have with rFVIIa treatment," Broderick explained ...

The U.S. cardiac resynchronization therapy market was valued at $965.6 million in 2019, and is projected to reach $983.3 million by 2027, registering a CAGR of 4.9% from 2020 to 2027. Surge in ...

After finding an intraventricular tumor in one clinical trial participant, the FDA placed a clinical hold on an experimental ...

Regenxbio (RGNX) shares rallied 5.4% in the last trading session to close at $11.6. This move can be attributable to notable volume with a higher number of shares being traded than in a typical ...

With the PDUFA date fast approaching for Regenxbio Inc.’s gene therapy RGX-121, the U.S. FDA placed the drug on clinical hold ...

A five-year-old patient dosed with RGX-111 has developed a brain tumour four years after being dosed with the gene therapy.

A central nervous system (CNS) tumor has prompted the FDA to place clinical holds on two Regenxbio gene therapies, including ...

Shares of Regenxbio plunged after the Food and Drug Administration placed clinical holds on two drug development programs ...

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of REGENXBIO Inc. ("Regenxbio" or "the Company") (NASDAQ: RGNX) for ...

REGENXBIO Inc. (Nasdaq: RGNX) today announced that the U.S. Food and Drug Administration (FDA) placed a clinical hold on its ...

ClearPoint Neuro is positioned for robust growth in 2026, driven by IRRAS, the PRISM 1.5T system clearance, and the company's new CRO facility. While the immediate future of uniQure's AMT-130 remains ...